Japan Congestive Heart Failure Drugs Market Size & Outlook

The congestive heart failure drugs market in Japan is expected to reach a projected revenue of US$ 1,093.1 million by 2030. A compound annual growth rate of 12.9% is expected of Japan congestive heart failure drugs market from 2022 to 2030.
Revenue, 2021 (US$M)
$367.3
Forecast, 2030 (US$M)
$1,093.1
CAGR, 2022 - 2030
12.9%
Report Coverage
Japan

Japan congestive heart failure drugs market, 2018-2030 (US$M)

Japan

Related Markets

Japan congestive heart failure drugs market highlights

  • The Japan congestive heart failure drugs market generated a revenue of USD 367.3 million in 2021 and is expected to reach USD 1,093.1 million by 2030.
  • The Japan market is expected to grow at a CAGR of 12.9% from 2022 to 2030.
  • In terms of segment, ace inhibitors was the largest revenue generating drug type in 2021.
  • Other Drug Types (Statins, including pipeline) is the most lucrative drug type segment registering the fastest growth during the forecast period.


Congestive heart failure drugs market data book summary

Market revenue in 2021USD 367.3 million
Market revenue in 2030USD 1,093.1 million
Growth rate12.9% (CAGR from 2021 to 2030)
Largest segmentAce inhibitors
Fastest growing segmentOther Drug Types (Statins, including pipeline)
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone antagonists, Inotropes, Other Drug Types (Statins, including pipeline)
Key market players worldwideBayer AG, Novartis AG ADR, Merck & Co Inc, AstraZeneca PLC ADR, Bristol-Myers Squibb Co, Amgen Inc, Boehringer Ingelheim, Pfizer Inc, Johnson & Johnson, Otsuka Pharmaceutical, Eli Lilly and Co, Novo Nordisk A/S ADR


Other key industry trends

  • In terms of revenue, Japan accounted for 6.0% of the global congestive heart failure drugs market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China congestive heart failure drugs market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,481.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Congestive Heart Failure Drugs Market Companies

Name Profile # Employees HQ Website

Japan congestive heart failure drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to congestive heart failure drugs market will help companies and investors design strategic landscapes.


Ace inhibitors was the largest segment with a revenue share of 32.89% in 2021. Horizon Databook has segmented the Japan congestive heart failure drugs market based on ace inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, other drug types (statins, including pipeline) covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Japan congestive heart failure drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan congestive heart failure drugs market databook

  • Our clientele includes a mix of congestive heart failure drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan congestive heart failure drugs market, including forecasts for subscribers. This country databook contains high-level insights into Japan congestive heart failure drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan congestive heart failure drugs market report size, by drug type, 2018-2030 (US$M)

Japan Congestive Heart Failure Drugs Market Share, 2021 & 2030 (US$M)

Japan congestive heart failure drugs market report size, by drug type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more